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COVID-19 challenge was one of the greatest ones in the 
last decades. It challenged not only the health care system 
but also many socio-economic aspects of human life. 
From the beginning of the story, there were several major 
concerns; including etiology, virology, pathology, and 
pathophysiology, the method of transmission, prevention, 
vaccination, detection, treatment, rehabilitation, etc (1). 
There was a general ambiguity in nearly every 
field; this was a great and inexperienced global dilemma. 
Everybody tried to do something; from 
Hydroxychloroquine and Azithromycin to claims to 
accept or reject the need for face masks. However, there 
was something vivid: though there were many similarities 
with its ancestors including the Spanish flu, COVID-19 
was born in the era of cellular and molecular medicine. 
From the early days, the new cellular and molecular 
medicine paradigm glimpsed as a potential solution for 
nearly every aspect of the disaster, including the Real-
time Polymerase Chain Reaction (RT-PCR) tests for the 
detection of viral infection (1,2). 
Many different pharmaceuticals were applied as 
repurposed drugs in the hope to overcome the disease, 
with their potential cellular and molecular explanations; 
though nearly all of them had considerable “Pro & Con”s. 
Meanwhile, from the first days of the virus outbreak, it 
was nearly clear that the most important bottleneck in 
controlling mortality would be the critical care of the 
patients. Again, this step was associated with different 
therapeutic approaches considering different outcome 
goals; from compassionate therapies to regenerative 
medicine approaches. Different ventilation support 
methods (invasive versus noninvasive), anti-
inflammatory approaches, antivirals, etc. are just 
examples of a large list of medical efforts to overcome the 
disease; though many have failed to gain success (3,4). 
The Journal of Cellular and Molecular Anesthesia 
started its commitment from the first days of the 
pandemic; trying to publish original researches as well as 
review articles, case reports, anecdotes, and letters, to do 
its commitment. Starting from the early weeks after the 
pandemic, the first articles of the Journal were published 
in the first week of April; a process now followed in the 
last issue of 2020. 
COVID-19 pandemic was a great challenge, 
however, it could open new windows for us, including but 
not limited to the breakthrough to produce mRNA 
vaccines. We might be encontered with other viral 
pandemics; however, lessons from the current pandemic 
was possibly a “Redemption” than “Perdition”. 
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